| Not Yet Recruiting | Liver Biopsy Following Gene Therapy For Hemophilia NCT05932914 | St. Jude Children's Research Hospital | — |
| Recruiting | Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With NCT07080905 | CSL Behring | Phase 3 |
| Withdrawn | Patient Interview Study to Explore the Impact of Gene Therapy in Hemophilia A & B NCT06634836 | Pfizer | — |
| Not Yet Recruiting | Synovial Proliferation on Routine Ultrasound: Active or Inactive? NCT06809972 | Van Creveldkliniek | — |
| Recruiting | BeCoMe-9: A Clinical Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia B NCT06611436 | Be Biopharma | Phase 1 / Phase 2 |
| Recruiting | An Open-Label, Comparative Study of the Efficacy, Safety and Pharmacodynamics of Single Dose of ANB-002 in Pat NCT06700096 | Biocad | Phase 3 |
| Recruiting | Longitudinal Cohort of Thrombosis and Hemostasis Diseases NCT06727669 | Peking University People's Hospital | — |
| Recruiting | Measurement Properties in People with Hemophilia NCT06565481 | University of Zurich | N/A |
| Enrolling By Invitation | ATHNdataset Registry NCT06820515 | American Thrombosis and Hemostasis Network | — |
| Recruiting | Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders NCT06147414 | Assistance Publique - Hôpitaux de Paris | — |
| Recruiting | A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131 NCT06379789 | Regeneron Pharmaceuticals | Phase 1 / Phase 2 |
| Active Not Recruiting | Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Chinese Subjects With Hemoph NCT06399289 | CSL Behring | Phase 3 |
| Terminated | The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC C NCT06568302 | ApcinteX Ltd | Phase 3 |
| Recruiting | A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (P NCT06349473 | Equilibra Bioscience LLC | Phase 1 |
| Recruiting | Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretre NCT06003387 | CSL Behring | Phase 3 |
| Active Not Recruiting | A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis W NCT05568459 | Regeneron Pharmaceuticals | — |
| Completed | Comparison of Efficiency of Closed Kinetic Chain Exercises Versus Proprioceptive Exercises Patient With Hemoph NCT05879549 | Bahçeşehir University | N/A |
| Unknown | Alterations in Coagulation Factor Levels in Patients With End Stage Liver Disease NCT06014320 | Stanford University | — |
| Unknown | Patterns of Hemophilia Care in Assiut Children Patients NCT05980377 | Assiut University | — |
| Enrolling By Invitation | Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec ( NCT05962398 | CSL Behring | — |
| Terminated | An 18-month Low-interventional Study to Assess Joint Health in Haemophilia A and B Patients on Prophylaxis Wit NCT05856266 | Swedish Orphan Biovitrum | Phase 4 |
| Unknown | Viscoelastic Properties of Lower Extremity Muscles in Patients With Hemophilia NCT05981313 | Hasan Kalyoncu University | — |
| Completed | Study of TU7710 in Warfarin Anti-coagulated Healthy Male Subjects NCT06025552 | TiumBio Co., Ltd. | Phase 1 |
| Terminated | A Study of SerpinPC in Participants with Hemophilia B (HemB) with Inhibitors NCT05789537 | ApcinteX Ltd | Phase 2 |
| Terminated | The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe He NCT05789524 | ApcinteX Ltd | Phase 2 |
| Recruiting | An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemop NCT06008938 | CSL Behring | — |
| Unknown | Reliability and Validity of the Turkish Version of the PedHAL NCT05889754 | Hasan Kalyoncu University | — |
| Recruiting | Study of the Safety, Pharmacodynamics and Efficacy of ANB-002 in Patients With Hemophilia B (SAFRAN) NCT06120582 | Biocad | Phase 1 / Phase 2 |
| Recruiting | The Efficacy and Safety of ZS801 in Chinese Hemophilia B Patients. NCT05630651 | Institute of Hematology & Blood Diseases Hospital, China | N/A |
| Recruiting | Gene Therapy for Hemophilia B Patients Aged 12-18 Years Old NCT05709288 | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 |
| Recruiting | Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophili NCT05568719 | Pfizer | Phase 3 |
| Recruiting | A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B NCT05611801 | Pfizer | Phase 3 |
| Terminated | Hemophilia Non-Interventional Study Prior to SerpinPC Intervention (PRESent-5) NCT05605678 | ApcinteX Ltd | — |
| Completed | Baby Detect : Genomic Newborn Screening NCT05687474 | Centre Hospitalier Universitaire de Liege | — |
| Unknown | Lead-in Study of VGB-R04 Gene Therapy for Hemophilia B-- An Observational Survey Analysis Study NCT05442528 | Shanghai Vitalgen BioPharma Co., Ltd. | — |
| Unknown | A Study to Evaluate the Safety and Efficacy of VGB-R04 in Adult Hemophilia B Patients NCT05441553 | Shanghai Vitalgen BioPharma Co., Ltd. | Phase 1 / Phase 2 |
| Unknown | Validation and Reliability of the CHO-KLAT in Turkish NCT05439642 | Yuzuncu Yil University | N/A |
| Unknown | Study of Surgical Practices in Patients With Haemophilia A or B Treated With an Extended Half-life Recombinant NCT06158334 | Hospices Civils de Lyon | — |
| Unknown | Clinical Study of Recombinant Human Activated Coagulation Factor VII for Injection in Patients With Hemophilia NCT05487976 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 3 |
| Recruiting | A Study to Evaluate the Safety and Efficacy of ZS801 in Adult Hemophilia B Patients NCT05641610 | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 / Phase 2 |
| Completed | Needs Assessment of Knowledge, Beliefs, and Attitudes of Patients With Hemophilia B About Gene Therapy NCT05044845 | St. Jude Children's Research Hospital | — |
| Active Not Recruiting | Evaluation of the Safety and Efficacy of Hemophilia B Gene Therapy Drug NCT05203679 | Shanghai Xinzhi BioMed Co., Ltd. | Phase 2 / Phase 3 |
| Recruiting | Safety and Tolerability of VGB-R04 in Patients With Haemophilia B NCT05152732 | Institute of Hematology & Blood Diseases Hospital, China | EARLY_Phase 1 |
| Terminated | Phase 1/2 Dose Confirmation Study of FLT180a in Hemophilia B NCT05164471 | Spur Therapeutics | Phase 1 / Phase 2 |
| Recruiting | Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors NCT05145127 | Pfizer | Phase 3 |
| Unknown | Pre-clinical Models for Mesenchymal Stem Cell Therapy in Hemophilic Arthropathy NCT05187936 | University Hospital, Montpellier | — |
| Completed | Vitamin K Antagonist Versus Direct Oral Anticoagulant Treatments in Hemophilia NCT05804734 | Groupe Maladies hémorragiques de Bretagne | — |
| Completed | Psychometric Validation of the Hemophilia Functional Ability Scoring Tool (Hemo-FAST) NCT04731701 | Swedish Orphan Biovitrum | — |
| Active Not Recruiting | Study of AAV5-hFIX in Severe or Moderately Severe Haemophilia B NCT05360706 | CSL Behring | — |
| Withdrawn | Medication Adherence and Non-adherence in Adults With Rare Disease NCT04541875 | Xperiome | — |
| Recruiting | National Longitudinal Cohort of Hematological Diseases NCT04645199 | Institute of Hematology & Blood Diseases Hospital, China | — |
| Active Not Recruiting | Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX NCT04628871 | Sangamo Therapeutics | — |
| Unknown | Lentiviral FIX Gene Therapy NCT03961243 | Shenzhen Geno-Immune Medical Institute | Phase 1 |
| Terminated | A Phase 1/2 Study of SHP648, an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia B Subjects NCT04394286 | Baxalta now part of Shire | Phase 1 / Phase 2 |
| Completed | Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Mod NCT03938792 | Pfizer | Phase 3 |
| Completed | AAV Gene Therapy Screening/Observational Protocol (ECLIPSE) NCT04272554 | Spur Therapeutics | — |
| Completed | Gaining Insight Into the Complexity of Pain in Patients With Haemophilia NCT05606640 | Universiteit Antwerpen | — |
| Completed | Nonacog Alfa Prophylaxis And Treatment Of Bleeding Episodes In Previously Treated Patients With Hemophilia B NCT04286412 | Pfizer | Phase 4 |
| Completed | Evaluation of a Recombinant Factor IX Product, APVO101, in Previously-Treated Pediatric Patients With Hemophil NCT03855280 | Medexus Pharma, Inc. | Phase 3 |
| Completed | Gene Therapy for Chinese Hemophilia B NCT04135300 | Institute of Hematology & Blood Diseases Hospital, China | N/A |
| Completed | Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia NCT04072237 | Catalyst Biosciences | Phase 1 |
| Completed | An International Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemoph NCT03901755 | Swedish Orphan Biovitrum | — |
| Completed | The Safety and Tolerability of SerpinPC in Healthy Men and in Men with Severe Blood Disorders (haemophilia a a NCT04073498 | ApcinteX Ltd | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Mod NCT03861273 | Pfizer | Phase 3 |
| Unknown | Personalized Medicine for Canadians With Hemophilia NCT03615053 | McMaster University | N/A |
| Completed | Study of Next-Generation Recombinant Factor IX Variant in Adult Subjects With Hemophilia B NCT03995784 | Catalyst Biosciences | Phase 2 |
| Unknown | Mutation p.Ile112Thr : Discrepancy Between Factor IX Level and Bleeding Phenotype NCT03946384 | Centre Hospitalier Universitaire Dijon | — |
| Completed | RIXUBIS PMS India (RIXUBIS PMS) NCT03565237 | Baxalta now part of Shire | Phase 4 |
| Enrolling By Invitation | Early Check: Expanded Screening in Newborns NCT03655223 | RTI International | — |
| Completed | ATHN 8: Previously Untreated Patients (PUPs) Matter Study NCT03818529 | American Thrombosis and Hemostasis Network | — |
| Completed | A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adu NCT03587116 | Pfizer | Phase 3 |
| Completed | Dose Confirmation Trial of AAV5-hFIXco-Padua NCT03489291 | CSL Behring | Phase 2 |
| Terminated | A Long-Term Follow-Up Study of Haemophilia B Patients Who Have Undergone Gene Therapy NCT03641703 | Spur Therapeutics | Phase 1 / Phase 2 |
| Completed | HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients NCT03569891 | CSL Behring | Phase 3 |
| Unknown | Web Accessible Population Pharmacokinetics Service - Hemophilia: Sources of Variability NCT03533504 | McMaster University | — |
| Completed | A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors NCT03417245 | Genzyme, a Sanofi Company | Phase 3 |
| Completed | A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors NCT03417102 | Genzyme, a Sanofi Company | Phase 3 |
| Recruiting | World Bleeding Disorders Registry NCT03327779 | World Federation of Hemophilia | — |
| Terminated | A Factor IX Gene Therapy Study (FIX-GT) NCT03369444 | University College, London | Phase 1 / Phase 2 |
| Completed | Joint Health Study NCT03358836 | Bloodworks | — |
| Terminated | Understanding Hemophilia A and B Drug Dosage Administration Patterns NCT03248141 | Pfizer | — |
| Active Not Recruiting | Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia NCT03307980 | Pfizer | Phase 2 |
| Completed | Global Epidemiologic Study of Preexisting Immunity to AAV in Adults With Severe Hemophilia NCT03185897 | Baxalta now part of Shire | — |
| Completed | Dose-escalation Study to Investigate the Safety, PK, and PD of ISU304/CB2679d in Hemophilia B Patients NCT03186677 | ISU Abxis Co., Ltd. | Phase 1 |
| Completed | Data Registry in Chinese Hemophilia A and B Patients NCT07101224 | Institute of Hematology & Blood Diseases Hospital, China | — |
| Completed | Non-Interventional Study to Capture the Patient Experience on Gene Therapy for Hemophilia Within the AskBio009 NCT03054389 | Baxalta now part of Shire | — |
| Completed | Post-Marketing Surveillance (Usage Results Study) of RIXUBIS in Adult and Pediatric Patients With Haemophilia NCT02922231 | Baxalta now part of Shire | — |
| Recruiting | German Pediatric Hemophilia Research Database NCT02912143 | Goethe University | — |
| Completed | Long-Term Safety, Tolerability, and Efficacy of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe H NCT02971969 | Ultragenyx Pharmaceutical Inc | — |
| Unknown | UK - EHL Outcomes Registry NCT02938156 | Royal Free Hospital NHS Foundation Trust | — |
| Completed | RIXUBIS Drug Use-Result Survey (Japan) NCT02937831 | Baxalta now part of Shire | — |
| Terminated | Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemo NCT02695160 | Sangamo Therapeutics | Phase 1 |
| Terminated | The Hemophilia Ultrasound Project NCT02807753 | University of Miami | — |
| Completed | Virtual Reality for Hemophilia NCT03507582 | Nationwide Children's Hospital | N/A |
| Completed | Treatment Patterns And Outcomes In Patients Treated With Benefix Or Refacto/Refacto AF - A Swedish Cohort Stud NCT02740413 | Pfizer | — |
| Completed | Ultrasonography in Hemophilic Joint Disease and Serum Markers NCT02634918 | Northwell Health | — |
| Terminated | Safety and Dose Finding Study of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B NCT02618915 | Ultragenyx Pharmaceutical Inc | Phase 1 / Phase 2 |
| Completed | A Gene Therapy Study for Hemophilia B NCT02484092 | Pfizer | Phase 2 |
| Completed | A Single Escalating Dose and Multiple Dose Study of BAY 1093884 in Subjects With Severe Hemophilia Types A or NCT02571569 | Bayer | Phase 1 |
| Completed | An Open-label Extension Study of an Investigational Drug, Fitusiran, in Patients With Moderate or Severe Hemop NCT02554773 | Genzyme, a Sanofi Company | Phase 1 / Phase 2 |
| Terminated | Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes NCT02392156 | Bioverativ Therapeutics Inc. | — |
| Completed | Trial of AAV5-hFIX in Severe or Moderately Severe Hemophilia B NCT02396342 | CSL Behring | Phase 1 / Phase 2 |
| Completed | A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B NCT02418793 | OPKO Health, Inc. | Phase 1 |
| Completed | An Open-Label, Single Dose Pharmacokinetic Study of Benefix (Recombinant Factor IX) in Male Chinese Subjects W NCT02213250 | Pfizer | Phase 1 |
| Completed | Web-based Application for the Population Pharmacokinetic Service - Phase 1 NCT02061072 | McMaster University | — |
| Completed | Safety and Efficacy of Benefix in Patients With Hemophilia B in Usual Care Settings in China NCT02336178 | Pfizer | Phase 4 |
| Completed | Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia B NCT02234310 | Bioverativ, a Sanofi company | Phase 3 |
| Terminated | A Study Comparing Factor Level and Inhibitor Titer Testing Results Drawn From Central Venous Lines and Venipun NCT02402829 | Children's Mercy Hospital Kansas City | — |
| Completed | Study of Prophylaxis, ACtivity and Effectiveness (SPACE) in Hemophilia Patients Currently Treated With ADVATE NCT02190149 | Baxalta now part of Shire | — |
| Withdrawn | Study of Recombinant Factor IX Product, IB1001, in Previously Treated Subjects With Hemophilia B NCT02048111 | Cangene Corporation | Phase 3 |
| Completed | A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Album NCT02053792 | CSL Behring | Phase 3 |
| Completed | A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B Patients NCT02035605 | Sanofi | Phase 1 |
| Completed | An Institutional Pilot Study to Investigate Physical Activity Patterns in Boys With Hemophilia NCT02199717 | The Hospital for Sick Children | — |
| Completed | Study on Von Willebrand Disease and Hemophilia in Cuenca, Ecuador NCT01589848 | Universidad del Azuay | — |
| Unknown | Global Hemostatic Methods in Hemophilia and Von Willebrand's Disease NCT02061033 | Karolinska University Hospital | — |
| Completed | Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen NCT01757405 | Baxalta now part of Shire | Phase 3 |
| Active Not Recruiting | Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With He NCT01687608 | Baxalta now part of Shire | Phase 1 / Phase 2 |
| Completed | A Safety, Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX Wi NCT01662531 | CSL Behring | Phase 3 |
| Completed | Viscosupplementation in Patients With Hemophilic Arthropathy NCT01748201 | University of Sao Paulo General Hospital | Phase 4 |
| Terminated | Hemophilia B Gene Therapy With AAV8 Vector NCT01620801 | Spark Therapeutics, Inc. | Phase 1 |
| Completed | Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Partici NCT01440946 | Bioverativ Therapeutics Inc. | Phase 3 |
| Completed | A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP NCT01496274 | CSL Behring | Phase 2 / Phase 3 |
| Completed | BAX 326 Pediatric Study NCT01488994 | Baxalta now part of Shire | Phase 2 / Phase 3 |
| Completed | BAX 326 Surgery Study in Hemophilia B Patients NCT01507896 | Baxalta now part of Shire | Phase 3 |
| Terminated | Osteoporosis and MRI Study in Hemophilia NCT01460147 | Baxalta now part of Shire | N/A |
| Completed | Study To Compare On-Demand Treatment To A Prophylaxis Regimen Of BeneFIX In Subjects With Moderately Severe to NCT01335061 | Pfizer | Phase 3 |
| Completed | A Safety and Efficacy Study of a Recombinant Factor IX in Patients With Severe Hemophilia B NCT01361126 | CSL Behring | Phase 1 / Phase 2 |
| Completed | Socialization of Adult Men With Congenital Hemophilia A or B NCT01510418 | Dana-Farber Cancer Institute | — |
| Completed | BAX 326 (rFIX) Continuation Study NCT01286779 | Baxalta now part of Shire | Phase 3 |
| Terminated | Study of Recombinant Factor IX Product, IB1001, in Previously Treated Pediatric Subjects With Hemophilia B NCT01271868 | Medexus Pharma, Inc. | Phase 3 |
| Completed | Safety and Pharmacokinetic Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein in Subjects Wit NCT01233440 | CSL Behring | Phase 1 |
| Completed | Comparing the Burden of Illness of Hemophilia in the Developing and the Developed World NCT01217255 | The Hospital for Sick Children | — |
| Completed | Pivotal Study (Pharmacokinetics, Efficacy, Safety) of BAX 326 (rFIX) in Hemophilia B Patients NCT01174446 | Baxalta now part of Shire | Phase 3 |
| Completed | IMMUNINE Pre-Treatment Study NCT01128881 | Baxalta now part of Shire | Phase 4 |
| Completed | Correlation Between Vitamin D Status and Bone Mineral Density in Patients With Hemophilia NCT01090206 | Virginia Commonwealth University | N/A |
| Completed | Dose-Escalation Study Of A Self Complementary Adeno-Associated Viral Vector For Gene Transfer in Hemophilia B NCT00979238 | St. Jude Children's Research Hospital | Phase 1 |
| Completed | BeneFIX Drug Use Results Survey [All-Case Surveillance] NCT01154231 | Pfizer | — |
| Terminated | Study of Ataluren (PTC124) in Hemophilia A and B NCT00947193 | PTC Therapeutics | Phase 2 |
| Completed | Study Evaluating Liver Transplantation in Haemophilia Patients in Spain NCT00927992 | Wyeth is now a wholly owned subsidiary of Pfizer | — |
| Completed | Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia NCT00851721 | Baxalta now part of Shire | Phase 3 |
| Completed | Study Evaluating On-Demand Treatment With BeneFIX In Chinese Subjects NCT00866606 | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 3 |
| Completed | Study of FVIIa Variant BAY86-6150 (B0189) in Subjects With Moderate or Severe Hemophilia Types A or B With or NCT01921855 | Bayer | Phase 1 |
| Completed | Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B NCT00768287 | Medexus Pharma, Inc. | Phase 2 / Phase 3 |
| Completed | Gait Evaluation in Haemophiliac Patients NCT00824798 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | — |
| Completed | Post Marketing Observational Study of Reformulated BeneFIX NCT00835068 | Pfizer | — |
| Completed | Phase I/IIa Study of FIXFc in Hemophilia B Patients NCT00716716 | Bioverativ Therapeutics Inc. | Phase 1 |
| Completed | Study Evaluating BeneFIX in Patients With Haemophilia B, Previously Treated With Plasma Derived Factor IX NCT00749476 | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 4 |
| Completed | Females With Severe or Moderate Hemophilia A or B: an International Multi-center Study NCT00936312 | Weill Medical College of Cornell University | — |
| Completed | Registry For Patients Treated With BeneFix In Usual Care Setting In Germany NCT00714415 | Pfizer | — |
| Completed | LTFU for Gene Transfer Subjects With Hemophilia B NCT00515710 | Spark Therapeutics, Inc. | — |
| Completed | Post Marketing Surveillance To Observe Safety and Efficacy Of BeneFIX In Patients With Hemophilia B NCT00484185 | Pfizer | — |
| Completed | Study Evaluating Approach to Treatment of Haemophilia A and B in Spain NCT00581438 | Wyeth is now a wholly owned subsidiary of Pfizer | — |
| Completed | Study Comparing On-Demand Treatment With Two Prophylaxis Regimens Of BeneFIX In Patients With Severe Hemophili NCT00364182 | Pfizer | Phase 3 |
| Completed | Study Evaluating Allergic Reactions To Benefix In Hemophilia B Patients NCT00244114 | Wyeth is now a wholly owned subsidiary of Pfizer | — |
| Completed | Efficacy and Safety of AlphaNine Versus BeneFIX in Patients With Severe Hereditary Haemophilia B NCT03091751 | Grifols Biologicals, LLC | Phase 2 |
| Completed | The Effect of Patient Counseling on Adolescent Hemophilia Patient Compliance With Bleeding Logs NCT00212459 | New York Presbyterian Hospital | N/A |
| Completed | Females With Severe or Moderate Hemophilia A or B: A Multi-Center Study NCT00936845 | Weill Medical College of Cornell University | — |
| Completed | Study to Describe the Allergic Reactions to Factor IX in Patients With Hemophilia B NCT00195221 | Wyeth is now a wholly owned subsidiary of Pfizer | — |
| Terminated | Safety of a New Type of Treatment Called Gene Transfer for the Treatment of Severe Hemophilia B NCT00076557 | Avigen | Phase 1 / Phase 2 |
| Completed | Post Marketing Study in Haemophilia B Patients Using Nonafact® (Human Coagulation Factor IX) NCT00139828 | Prothya Biosolutions | Phase 4 |
| Completed | Study Evaluating rFIX; BeneFIX in Severe Hemophilia B NCT00037557 | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 3 |
| Completed | Prospective Registry of European Hemophilia B Patients Receiving BeneFIX® for Usual Use NCT00167973 | Wyeth is now a wholly owned subsidiary of Pfizer | — |
| Completed | Study Evaluating BENEFIX in Previously Treated Patients With Hemophilia B NCT00581126 | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 4 |
| Completed | Phase I/II Study of Monoclonal Factor IX Concentrate for Factor IX Deficiency NCT00004801 | National Center for Research Resources (NCRR) | Phase 1 / Phase 2 |
| Completed | Study Evaluating rFIX; BeneFIX® in Hemophilia B NCT00093171 | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 3 |
| Completed | Study Evaluating of Recombinant Human Factor IX (BeneFIX) and a New Formulation of BeneFIX (rFIX-R) in Moderat NCT00093210 | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 3 |